PT - JOURNAL ARTICLE AU - Marchalot, Anne AU - Lambert, Jean-Marie AU - Boyer, François AU - Pollet, Justine AU - Moreau, Jeanne AU - Feuillard, Jean AU - Faumont, Nathalie AU - Delpy, Laurent TI - Splice switching oligonucleotide mediated gene knockdown in B cells and plasma cells AID - 10.1101/2020.09.18.302984 DP - 2020 Jan 01 TA - bioRxiv PG - 2020.09.18.302984 4099 - http://biorxiv.org/content/early/2020/09/18/2020.09.18.302984.short 4100 - http://biorxiv.org/content/early/2020/09/18/2020.09.18.302984.full AB - The need to identify new therapeutic approaches to the treatment of cancers of the B lymphoid lineage is crucial. Unlike CRISPR/Cas technology, antisense strategies result in transient modifications of gene expression and lack mutagenic effects at the DNA level. Here, we provide evidence for efficient knockdown of c-REL and RELA expression after treatment with splice switching antisense oligonucleotides (SSO) inducing exon skipping and reading frameshifts. We also developed a tool to facilitate the choice of exons for on purpose inhibition of mouse and human gene expression. Interestingly, treatments with morpholino SSO targeting the c-REL exon 2 donor splice site or RELA exon 5 acceptor splice site elicited very efficient knockdown in diffuse large B cell lymphoma (DLBCL) cell lines and antibody-secreting cells derived from primary human B cells. Consistent with the clinical relevance of c-REL activation in DLBCLs, treatment with c-REL SSO induced major alterations in NF-κB and TNF signalling pathways and strongly decreased cell viability. Altogether, SSO-mediated knockdown is a powerful approach to transiently inhibit the expression of given genes in B-lineage cells that should pave the way for cancer treatments, provided optimized ligand-conjugations for in vivo delivery.Competing Interest StatementThe authors have declared no competing interest.